A photo of Brian Weiss.

Director, Neuroblastoma Program

Associate Director, Oncology Clinical Research

Associate Director, Safety and Compliance

Professor, UC Department of Pediatrics

513-636-9863

513-636-3549

Board Certified

My Biography & Research

Biography

Brian Weiss is a professor of Clinical Pediatrics in the Cancer and Blood Diseases Institute at Cincinnati Children’s Hospital Medical Center where he specializes in benign tumors in patients with Neurofibromatosis Type 1 (NF1) and directs the Neuroblastoma Program. In addition to serving as associate director of clinical research for Oncology and associate director for Safety and Compliance, Dr. Weiss has spearheaded efforts to reduce chemotherapy errors and leads national trials in high risk neuroblastoma, targeted radiotherapy, and targeted drugs for NF1 associated plexiform neurofibromas.

Clinical Interests

Targeted agents for neurofibromatosis type 1-related plexiform neurofibromas and other solid tumors; new therapies for high-risk neuroblastoma, including 131I-MIBG treatment and other new approaches to targeting and killing neuroblastoma cells.

Academic Affiliation

Professor, UC Department of Pediatrics

Divisions

Cancer and Blood Diseases, Neuroblastoma, Neurofibromatosis, Rasopathy, Oncology, Cancer and Blood Diseases

My Locations

My Education

MD: Northwestern University Medical School, Chicago, IL, 1993.

Residency and Chief Residency: Pediatrics, University of California, San Francisco, CA, 1993-1997.

Fellowship: Pediatric Hematology/Oncology, University of California, San Francisco, CA, 1997-2000.

Certification: National Medical Board; Pediatrics;1996, 2002; Pediatric Hematology-Oncology, 2000, 2007.

My Publications

Selected Publication

High-dose Carboplatin/Etoposide/Melphalan increases risk of thrombotic microangiopathy and organ injury after autologous stem cell transplantation in patients with neuroblastoma. Jodele, S; Dandoy, CE; Myers, K; Wallace, G; Lane, A; Teusink-Cross, A; Weiss, B; Davies, SM. Bone Marrow Transplantation. 2018; 53:1311-1318.

Sentinel lymph node biopsy in head and neck rhabdomyosarcoma. Turpin, B; Pressey, JG; Nagarajan, R; Weiss, BD; Trout, AT; Gelfand, MJ; Pater, L; Vatner, RE; Breneman, JC; Dasgupta, R. Pediatric Blood and Cancer. 2019; 66:e27532-e27532.

Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma. DuBois, SG; Mosse, YP; Fox, E; Kudgus, RA; Reid, JM; McGovern, R; Groshen, S; Bagatell, R; Maris, JM; Twist, CJ; et al. Clinical Cancer Research. 2018; 24:6142-6149.

2016 Children's Tumor Foundation conference on neurofibromatosis type 1, neurofibromatosis type 2, and schwannomatosis. Fisher, MJ; Belzberg, AJ; de Blank, P; De Raedt, T; Elefteriou, F; Ferner, RE; Giovannini, M; Harris, GJ; Kalamarides, M; Karajannis, MA; et al. American Journal of Medical Genetics, Part A. 2018; 176:1258-1269.

Change in liver, spleen and bone marrow magnetic resonance imaging signal intensity over time in children with solid abdominal tumors. Sirignano, M; Dillman, JR; Weiss, BD; Quinn, CT; Zhang, B; Su, W; Trout, AT. Pediatric Radiology: roentgenology, nuclear medicine, ultrasonics, CT, MRI. 2018; 48:325-332.

Expression of Five Neuroblastoma Genes in Bone Marrow or Blood of Patients with Relapsed/Refractory Neuroblastoma Provides a New Biomarker for Disease and Prognosis. Marachelian, A; Villablanca, JG; Liu, CW; Liu, B; Goodarzian, F; Lai, HA; Shimada, H; Tran, HC; Parra, JA; Gallego, R; et al. Clinical Cancer Research. 2017; 23:5374-5383.

Congenital Sucrase-isomaltase Deficiency: A Novel Compound Heterozygous Mutation Causing Aberrant Protein Localization. Haberman, Y; Di Segni, A; Loberman-Nachum, N; Barel, O; Kunik, V; Eyal, E; Kol, N; Hout-Siloni, G; Kochavi, B; Avivi, C; et al. Journal of Pediatric Gastroenterology and Nutrition. 2017; 64:770-776.

Significant and Sustained Reduction in Chemotherapy Errors Through Improvement Science. Weiss, BD; Scott, M; Demmel, K; Kotagal, UR; Perentesis, JP; Walsh, KE. (2017) American Society of Clinical Oncology (ASCO). 13:e329-e336.

Single and multidimensional measurements underestimate neuroblastoma response to therapy. Trout, AT; Towbin, AJ; Klingbeil, L; Weiss, BD; von Allmen, D. Pediatric Blood and Cancer. 2017; 64:18-24.

Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas. Dombi, E; Baldwin, A; Marcus, LJ; Fisher, MJ; Weiss, B; Kim, A; Whitcomb, P; Martin, S; Aschbacher-Smith, LE; Rizvi, TA; et al. The New England journal of medicine. 2016; 375:2550-2560.